🔗 Share this article

As the United States proceeds with unprecedented revisions to its immunization schedules, one figure has surfaced in a surprising turn: Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about COVID-19 shots in the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her short tenure at the FDA.

Proposed Changes to Childhood Vaccine Schedule

Public health authorities had intended to unveil radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would place the US at odds with many the world with insufficient data for public health gain. The announcement has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to head the center this year.

A New Direction at the Agency

This interim role could signify a closer partnership between the drug and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting specific childhood immunization guidelines in the US in order to be more like the Danish model, a nation with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

To date statements, she has continued to focus on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Høeg has little discernible track record in pharmaceutical research, approval processes or leadership, which has been typical for previous directors of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she lacks the sort of resume that prior appointees who ran the center have had.”

CDER has an immense portfolio at the agency, Woodcock emphasized.

“Many people just focuses on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars division, OTC medication office and more, and each of these must be looked after,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a significant management component to the position, which supervises over 5,000 employees. “It is a huge administrative position, if you execute it properly,” she said.

Response and Disputed Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson said that the “inquiries rely on inaccurate premises”.

“Her experience is consistent with the duties of her position,” the representative said, pointing to the months Høeg spent counseling the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed expedited medication authorization process that apparently troubled her predecessors. “By what process are these drugs being picked for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, except for vaccines.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, track record, critics said. She published a analysis using unconfirmed volunteer-provided data to assess the rate of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed altering regulations for recently developed shots and halting “non-essential” immunizations, she stated following the vote on a online show. At the FDA, Høeg has according to sources floated the idea of barring adolescent males from getting COVID-19 vaccines.

“She’s an complete dogmatist who starts off with her beliefs and tailors the evidence to accommodate the evidence in a extremely misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other dissenters, {like|